Patent ID: 9491934
Filing Date: 2016-11-15
CPC Classification: A01K,A61K,A61P,C07K,C12N,C12Q,G01N

Claim Text:
1. A method of inhibiting expression of an endogenous cellular CCR5 gene in an isolated human cell, the method comprising the step of: introducing first and second different non-naturally occurring fusion proteins into the cell, wherein at least one of the first and second fusion proteins is introduced into the cell as a nucleic acid, each fusion protein comprising a non-naturally occurring zinc finger protein and a heterologous endonuclease domain wherein the endogenous cellular CCR5 gene is in its normal genomic and chromatin context and is not heterologous to the cell, wherein the zinc finger protein of the first fusion protein is engineered to bind to a first target site and the zinc finger protein of the second fusion protein is engineered to bind to a second target site and the first and second target sites are in the coding region of the endogenous cellular CCR5 gene in its normal genomic and chromatin context and further wherein the first and second fusion proteins contact the first and second target sites in the endogenous cellular CCR5 gene; thereby inhibiting expression of the endogenous cellular CCR5 gene.